Evidence map›Paper›PMID 25879470›Full record

ArticleBMC complementary and alternative medicine2015

In-silico prediction of drug targets, biological activities, signal pathways and regulating networks of dioscin based on bioinformatics.

Lianhong Yin, Lingli Zheng, Lina Xu, Deshi Dong, Xu Han, Yan Qi, Yanyan Zhao, Youwei Xu, Jinyong Peng

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lianhong YinCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. yinlianhong1015@163.com.
Lingli ZhengThe First Affiliated Hospital of Dalian Medical University, Dalian, 116022, China. zheng_ll2009@126.com.
Lina XuCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. Linaxu_632@126.com.
Deshi DongThe First Affiliated Hospital of Dalian Medical University, Dalian, 116022, China. Jihongyao_361@163.com.
Xu HanCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. Xuhan2002zs@163.com.
Yan QiCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. Yanqi_1976@163.com.
Yanyan ZhaoCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. Yanyanzhao_2009@126.com.
Youwei XuCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. Youweixu_1964@163.com.
Jinyong PengCollege of Pharmacy, Dalian Medical University, Western 9 Lvshun South Road, Dalian, 116044, China. jinyongpeng2005@163.com.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInverse docking technology has been a trend of drug discovery, and bioinformatics approaches have been used to predict target proteins, biological activities, signal pathways and molecular regulating networks affected by drugs for further pharmacodynamic and mechanism studies.

methodsIn the present paper, inverse docking technology was applied to screen potential targets from potential drug target database (PDTD). Then, the corresponding gene information of the obtained drug-targets was applied to predict the related biological activities, signal pathways and processes networks of the compound by using MetaCore platform. After that, some most relevant regulating networks were considered, which included the nodes and relevant pathways of dioscin.

results71 potential targets of dioscin from humans, 7 from rats and 8 from mice were screened, and the prediction results showed that the most likely targets of dioscin were cyclin A2, calmodulin, hemoglobin subunit beta, DNA topoisomerase I, DNA polymerase lambda, nitric oxide synthase and UDP-N-acetylhexosamine pyrophosphorylase, etc. Many diseases including experimental autoimmune encephalomyelitis of human, temporal lobe epilepsy of rat and ankylosing spondylitis of mouse, may be inhibited by dioscin through regulating immune response alternative complement pathway, G-protein signaling RhoB regulation pathway and immune response antiviral actions of interferons, etc. The most relevant networks (5 from human, 3 from rat and 5 from mouse) indicated that dioscin may be a TOP1 inhibitor, which can treat cancer though the cell cycle- transition and termination of DNA replication pathway. Dioscin can down regulate EGFR and EGF to inhibit cancer, and also has anti-inflammation activity by regulating JNK signaling pathway.

conclusionsThe predictions of the possible targets, biological activities, signal pathways and relevant regulating networks of dioscin provide valuable information to guide further investigation of dioscin on pharmacodynamics and molecular mechanisms, which also suggests a practical and effective method for studies on the mechanism of other chemicals.

Indexed as

Gene Regulatory NetworksAnimalsAnti-Inflammatory AgentsAntineoplastic Agents, PhytogenicCell CycleComputational BiologyDioscoreaDiosgeninDNA Topoisomerases, Type IDown-RegulationDrugs, Chinese HerbalEpidermal Growth FactorErbB ReceptorsHumansMaleMAP Kinase Signaling SystemAnti-Inflammatory AgentsAntineoplastic Agents, PhytogenicdioscinDiosgeninDNA Topoisomerases, Type IDrugs, Chinese HerbalEGFR protein, humanEpidermal Growth FactorErbB ReceptorsTOP1 protein, human

Identifiers

PMID25879470
PMCPMC4354738
OpenAlexW2027055498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.